Purpose: Background: Puumala hantavirus (PUUV) is the main cause of hemorrhagic fever with renal syndrome (HRFS) in Russia. Although known to cause HFRS endemic in the Republic of Tatarstan (RT), little is known about the genetic diversity of PUUV in the Republic. Therefore, we sought to characterize variations in PUUV S-segment in bank voles in the RT.
Purpose: Hantaviruses (Hantaviridae) cause two types of life-threatening human diseases, hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus cardiopulmonary syndrome (HCPS) in the Americas. To date, as a consensus, wild rodents were believed as natural hosts of hantaviruses. However, recent studies described several novel hantaviruses in shrews, moles and bats, suggesting the dispersal of hantaviruses in several animal taxa during their evolution. Interestingly, the co-evolutionary analyses of most recent studies have raised the possibility of bats and/or soricomorphs may have served as the primordial mammalian host and harboured the ancestors of rodent-borne hantaviruses.The aim of our study was to investigate the presence of hantaviruses in bat lung tissue homogenates originally collected for taxonomic purposes in Malaysia, 2015.
Methods & Materials: Hantavirus specific nested PCR screening of 116 samples targeting the L segment of the virus have revealed the positivity of two lung tissue homogenates originating from Murina aenea bat species.
Results: The obtained results indicate the first molecular evidence for hantavirus in Murina eanae bat species.
Conclusion: Preliminary sequence analysis of the PCR amplicon suggest the identified virus may represents a novel species within Orthohantavirus genus. Furthermore, our results provide additional genomic data to help extend our knowledge about the evolution of these viruses and we present the first hantavirus sequence from Murina bat genus. https://doi.org/10.1016/j.ijid.2018.11.289 Conclusion: Kabylia remains an active focus for CanL with a high prevalence; this epidemiological situation requires the implementation of a national program against this protozoosis. This study highlights, for the first time, L. infantum in equids from Algeria which suggests the possible involvement of these animals in the epidemiological chain of L. infantum in high-transmission areas. This preliminary study deserves further investigation due to the lack of equids. https://doi.org/10.1016/j.ijid.2018.11.290
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Phase 2 Previously, the safety and immunogenicity was demonstrated in a Phase 1 clinical trial (EudraCT: 2013-001084-23). Here, we will present the final data of a Phase 2 clinical trial in 263 healthy, volunteer adults (NCT02861586). Chikungunya is a rapidly spreading viral disease affecting significant parts of the Americas, India and South East Asia. In the majority of patients, the febrile acute disease turns into a chronic disease causing severe, debilitating arthritis that can last years post-infection. So far, no vaccine or treatment has been licensed.
Methods & Materials: The clinical trial was double blinded, randomized, active -and placebo-controlled, with the objective to evaluate the optimal dose of MV-CHIK vaccine in regard to immunogenicity, safety and tolerability in healthy adult volunteers. Immune responses were determined by induction of neutralizing antibodies by plaque reduction neutralization titer (PRNT).
Results: The vaccine presents with a safety profile in humans that is comparable to the approved control vaccine in the trial. Overall frequency of solicited and unsolicited adverse events (AEs) was low (not more than 30%) and all events were transient. No vaccine related Serious AEs (SAE) were observed. The vaccine induced neutralizing antibodies after a single immunization in up to 93% in the high dose group. A boost substantially increased the neutralizing antibody titers and seroconversion rate. In addition, CHIKV specific T-cell responses were induced following vaccination. Interestingly, the vaccine induced a functional immune response even in the presence of pre-existing anti-measles immunity as demonstrated in a subset of subjects who received a measles prime immunization prior to the Chikungunya vaccine.
Conclusion: The data show that the live recombinant MV-CHIK vaccine is a safe and tolerable vaccine that induces a robust immune response. The data clearly path the way for the preparation of a late stage clinical development program. 
